ERBB2 and breast carcinoma: (74) retrospectively analyzed the immunohistochemical data of 504 breast cancer patients, and found that the expression rate of AGR2 in luminal A (n=226) was 50.4%, in luminal B (n=191) was 50.3%, in HER2-OE (n=40) was 35%, and in triple negative diseases was 4.3% (basal-like breast cancer, BLBC was 4.8%, unclassified was 3.8%).